Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

David M. Ashley, Brenda Faiola, Smita Nair, Laura P. Hale, Darell D. Bigner, Eli Gilboa

Research output: Contribution to journalArticle

375 Citations (Scopus)

Abstract

Recent studies have shown that the brain is not a barrier to successful active immunotherapy that uses gene-modified autologous tumor cell vaccines. In this study, we compared the efficacy of two types of vaccines for the treatment of tumors within the central nervous system (CNS): dendritic cell (DC)-based vaccines pulsed with either tumor extract or tumor RNA, and cytokine gene-modified tumor vaccines. Using the B16/F10 murine melanoma (B16) as a model for CNS tumor, we show that vaccination with bone marrow- generated DCs, pulsed with either B16 cell extract or B16 total RNA, can induce specific cytotoxic T lymphocytes against B16 tumor cells. Both types of DC vaccines were able to protect animals from tumors located in the CNS. DC-based vaccines also led to prolonged survival in mice with tumors placed before the initiation of vaccine therapy. The DC-based vaccines were at least as effective, if not more so, as vaccines containing B16 tumor cells in which the granulocytic macrophage colony-stimulating factor gene had been modified. These data support the use of DCbased vaccines for the treatment of patients with CNS tumors.

Original languageEnglish
Pages (from-to)1177-1182
Number of pages6
JournalJournal of Experimental Medicine
Volume186
Issue number7
DOIs
StatePublished - Oct 6 1997
Externally publishedYes

Fingerprint

Central Nervous System Neoplasms
Dendritic Cells
Immunity
Vaccines
Bone Marrow
RNA
Neoplasms
Active Immunotherapy
Cancer Vaccines
Genes
Experimental Melanomas
Macrophage Colony-Stimulating Factor
Cytotoxic T-Lymphocytes
Cell Extracts
Vaccination
Central Nervous System
Cytokines
Survival
Brain
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. / Ashley, David M.; Faiola, Brenda; Nair, Smita; Hale, Laura P.; Bigner, Darell D.; Gilboa, Eli.

In: Journal of Experimental Medicine, Vol. 186, No. 7, 06.10.1997, p. 1177-1182.

Research output: Contribution to journalArticle

Ashley, David M. ; Faiola, Brenda ; Nair, Smita ; Hale, Laura P. ; Bigner, Darell D. ; Gilboa, Eli. / Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. In: Journal of Experimental Medicine. 1997 ; Vol. 186, No. 7. pp. 1177-1182.
@article{75a1dd57a10746b7bf6762b771decc85,
title = "Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors",
abstract = "Recent studies have shown that the brain is not a barrier to successful active immunotherapy that uses gene-modified autologous tumor cell vaccines. In this study, we compared the efficacy of two types of vaccines for the treatment of tumors within the central nervous system (CNS): dendritic cell (DC)-based vaccines pulsed with either tumor extract or tumor RNA, and cytokine gene-modified tumor vaccines. Using the B16/F10 murine melanoma (B16) as a model for CNS tumor, we show that vaccination with bone marrow- generated DCs, pulsed with either B16 cell extract or B16 total RNA, can induce specific cytotoxic T lymphocytes against B16 tumor cells. Both types of DC vaccines were able to protect animals from tumors located in the CNS. DC-based vaccines also led to prolonged survival in mice with tumors placed before the initiation of vaccine therapy. The DC-based vaccines were at least as effective, if not more so, as vaccines containing B16 tumor cells in which the granulocytic macrophage colony-stimulating factor gene had been modified. These data support the use of DCbased vaccines for the treatment of patients with CNS tumors.",
author = "Ashley, {David M.} and Brenda Faiola and Smita Nair and Hale, {Laura P.} and Bigner, {Darell D.} and Eli Gilboa",
year = "1997",
month = "10",
day = "6",
doi = "10.1084/jem.186.7.1177",
language = "English",
volume = "186",
pages = "1177--1182",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "7",

}

TY - JOUR

T1 - Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

AU - Ashley, David M.

AU - Faiola, Brenda

AU - Nair, Smita

AU - Hale, Laura P.

AU - Bigner, Darell D.

AU - Gilboa, Eli

PY - 1997/10/6

Y1 - 1997/10/6

N2 - Recent studies have shown that the brain is not a barrier to successful active immunotherapy that uses gene-modified autologous tumor cell vaccines. In this study, we compared the efficacy of two types of vaccines for the treatment of tumors within the central nervous system (CNS): dendritic cell (DC)-based vaccines pulsed with either tumor extract or tumor RNA, and cytokine gene-modified tumor vaccines. Using the B16/F10 murine melanoma (B16) as a model for CNS tumor, we show that vaccination with bone marrow- generated DCs, pulsed with either B16 cell extract or B16 total RNA, can induce specific cytotoxic T lymphocytes against B16 tumor cells. Both types of DC vaccines were able to protect animals from tumors located in the CNS. DC-based vaccines also led to prolonged survival in mice with tumors placed before the initiation of vaccine therapy. The DC-based vaccines were at least as effective, if not more so, as vaccines containing B16 tumor cells in which the granulocytic macrophage colony-stimulating factor gene had been modified. These data support the use of DCbased vaccines for the treatment of patients with CNS tumors.

AB - Recent studies have shown that the brain is not a barrier to successful active immunotherapy that uses gene-modified autologous tumor cell vaccines. In this study, we compared the efficacy of two types of vaccines for the treatment of tumors within the central nervous system (CNS): dendritic cell (DC)-based vaccines pulsed with either tumor extract or tumor RNA, and cytokine gene-modified tumor vaccines. Using the B16/F10 murine melanoma (B16) as a model for CNS tumor, we show that vaccination with bone marrow- generated DCs, pulsed with either B16 cell extract or B16 total RNA, can induce specific cytotoxic T lymphocytes against B16 tumor cells. Both types of DC vaccines were able to protect animals from tumors located in the CNS. DC-based vaccines also led to prolonged survival in mice with tumors placed before the initiation of vaccine therapy. The DC-based vaccines were at least as effective, if not more so, as vaccines containing B16 tumor cells in which the granulocytic macrophage colony-stimulating factor gene had been modified. These data support the use of DCbased vaccines for the treatment of patients with CNS tumors.

UR - http://www.scopus.com/inward/record.url?scp=0030808677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030808677&partnerID=8YFLogxK

U2 - 10.1084/jem.186.7.1177

DO - 10.1084/jem.186.7.1177

M3 - Article

C2 - 9314567

AN - SCOPUS:0030808677

VL - 186

SP - 1177

EP - 1182

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 7

ER -